University of Groningen

The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects

Sipos, P.M.; Loos, B.G.; Abbas, F.; Timmerman, M.F.; Velden, U. van der

Published in:
Journal of Clinical Periodontology

DOI:
[10.1111/j.1600-051X.2005.00754.x](https://doi.org/10.1111/j.1600-051X.2005.00754.x)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2005

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Sipos, P. M., Loos, B. G., Abbas, F., Timmerman, M. F., & Velden, U. V. D. (2005). The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. *Journal of Clinical Periodontology*, 32(7), 765-772.
<https://doi.org/10.1111/j.1600-051X.2005.00754.x>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects

P. M. Sipos^{1,2}, B. G. Loos¹,
F. Abbas^{1,3}, M. F. Timmerman¹
and U. van der Velden¹

¹Department of Periodontology, Academic Center for Dentistry Amsterdam (ACTA), Amsterdam; ²Royal Netherlands Navy Dental Services and; ³Department of Periodontology, Oral Health Institute, University of Groningen, Groningen, the Netherlands

Sipos PM, Loos BG, Abbas F, Timmerman MF, van der Velden U. The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. *J Clin Periodontol* 2005; 32: 765–772. doi: 10.1111/j.1600-051X.2005.00754.x. © Blackwell Munksgaard 2005.

Abstract

Objectives: The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel[®]) in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex[®]).

Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured.

Results: After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86 ± 0.75 mm, a mean gain in CAL of 1.28 ± 2.04 mm, a mean PBL gain of 1.63 ± 1.21 mm and a mean increase of recession (REC) of 1.56 ± 2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02 ± 1.55 mm, a mean gain in CAL of 1.65 ± 1.29 mm, a mean PBL gain of 1.58 ± 1.92 mm and a mean increase of REC of 1.38 ± 1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects.

Conclusion: Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.

Key words: barrier membranes; enamel matrix proteins; GTR; intra-osseous defects; tetracycline

Accepted for publication 13 December 2004

A relatively new biological concept in the attempts to obtain periodontal regeneration is the use of enamel matrix proteins (EMP). In vitro studies have demonstrated that EMP stimulate attachment, growth and metabolism of periodontal ligament fibroblasts (Hoang et al. 2000, Van der Pauw et al. 2000,

Lyngstadaas et al. 2001), but not gingival fibroblasts (Gestrelus et al. 1997b). EMP absorb to hydroxyapatite, collagen and denuded dental roots (Gestrelus et al. 1997a). Furthermore, it has been suggested that EMP applied to teeth may have an inhibitory effect on the formation of the oral biofilm

(Arweiler et al. 2002, Spahr et al. 2002).

Comparable reduction of probing pocket depth (PPD), a gain in probing attachment level and, in some studies, a gain in alveolar bone have been accomplished after guided tissue regeneration (GTR) and application of EMP (Cortel-

lini et al. 1996, Bouchard et al. 1997, Caffesse et al. 1997, Hammarström et al. 1997, Heden et al. 1999, Heijl 1997, Heijl et al. 1997, Smith MacDonald et al. 1998, Mellonig 1999, Pontoriero et al. 1999, Sculean et al. 1999a,b,c, Heden 2000, Froum et al. 2001, Loos et al. 2002, Abbas et al. 2003). However, a variation of clinical outcome and predictability is reported for GTR as well as EMP (Tonetti & Cortellini 1997, Tonetti et al. 1998, 2002, Heden et al. 1999, Loos et al. 2002).

In contrast to EMP, barrier membranes are thought to control healing dynamics by covering the periodontal defect. The gingival tissues (epithelium and connective tissue) are prevented from contacting the root surface during early healing, and may thus provide space for cells originating from the periodontal ligament to re-populate the previously affected root surface. This may induce regeneration of the lost periodontal tissues (Gottlow et al. 1986). One important aspect jeopardizing a predictable and successful outcome concerns bacterial infection of the healing intra-osseous defect (Slots et al. 1999). It has been suggested that the immediate post-operative infection by periodontal pathogens of the treated defect and colonization of the membrane itself may be one reason for lack of results in some cases (Selvig et al. 1992, Mombelli et al. 1993). For example, periodontal pathogens may colonize membranes within 3 min. of intra-oral manipulation. The presence of bacteria on the membrane surface facing the gingiva at 6 weeks postoperatively has been shown to be a statistically significant negative predictor of gain in clinical attachment (Nowzari et al. 1996).

Controlling the bacterial colonization in the early healing phase and reducing the spread of infections may increase the predictability of results (Zucchelli et al. 2000). Several antimicrobial agents have been shown to be inhibitory for bacteria associated with destructive periodontal disease (Walker et al. 1985). The use of systemic antibiotics have therefore been propagated by many researchers investigating regenerative procedures for the treatment of intra-osseous defects (Van Winkelhoff et al. 1996, Cortellini & Tonetti 2000, Kornman & Robertson 2000). Compared with systemically delivered antibiotics, locally controlled-release delivery devices applied professionally may exhibit several benefits: independence

of patient compliance, enhanced or improved pharmacokinetic response, greater access and the ability to position the drug adjacent to the disease and to deliver a lower total dosage of the drug to the patient but giving a more controlled concentration at the diseased site (Goodson 1989). Few studies are known using local antimicrobial devices in the treatment of intra-osseous defects. The use of topical 25% metronidazole gel in GTR was shown to be more effective in preventing membrane contamination, but did not improve clinical outcomes (Zucchelli et al. 1999). A study using a tetracycline-coated expanded polytetrafluoroethylene (e-PTFE) barrier membrane suggested that the antimicrobial properties of tetracycline during initial healing could result in additional gain of clinical periodontal attachment (Zarkesh et al. 1999).

Controlled clinical studies comparing the use of EMP and bioresorbable membranes and combinations of both showed no significant difference between any treatment modality in gain of clinical attachment and bone (Sculean et al. 1999a,b,c, 2000, 2001a,b, Silvestri et al. 2000). However, in these studies, the adjunctive use of tetracycline attached to an e-PTFE barrier membrane to control early membrane infection has not been investigated.

Therefore, the aim of this study was to evaluate, in a split-mouth randomized-controlled clinical trial, the clinical response of EMP in the treatment of intra-osseous defects with or without a GTR technique using a tetracycline-coated e-PTFE barrier membrane.

Material and Methods

Subjects and inclusion criteria

Initially, 18 consecutive untreated periodontitis patients, in the age range of 18–55 years, referred to the Department of Periodontology at ACTA, were recruited, in good general health, with at least two intra-osseous defects fulfilling the criteria of ≥ 6 mm pocket depth and ≥ 4 mm radiographic depth not adjacent to a molar furcation site. The defects could be located on any tooth, except the upper molars. The teeth at the defect sites had to have vital pulps, as assessed by sensitivity to a cold test using ethyl chloride to exclude endodontic complications. Smoking habits were recorded, and smoking was quantified as the number of packyears

(number of packs of cigarettes smoked per day $\times$ number of years smoked) (Grossi et al. 1995). The patients were informed about the aim of the study verbally and in writing, and they signed an informed consent before participation.

Pre-trial treatment

Each patient received a minimum of 6 h of pre-trial initial treatment consisting of meticulous oral hygiene instructions and supra- and subgingival debridement with manual and ultrasonic instruments using local anaesthetics. Patients who were culture positive for *Actinobacillus actinomycetemcomitans* 3 months after initial therapy received treatment of 1 h by means of re-scaling and root planing in conjunction with systemic antibiotics (375 mg amoxicillin TID and 250 mg metronidazole TID) for 1 week. Sites unrelated to the selected intra-osseous defects that showed at re-evaluation, i.e. 3 months after the completion of the initial therapy, residual PPD of ≥ 6 mm were treated by conventional periodontal surgery. The selected experimental intra-osseous sites and sites with a residual PPD of 4–5 mm received an extra session of subgingival debridement under local anaesthetics.

Final patient selection

The subjects had to demonstrate the ability to perform good oral hygiene, by having a full-mouth plaque score of $< 20\%$ in two consecutive screening sessions prior to the final selection; if not, they were excluded from the study. Patients using antibiotics were admitted for the final selection at least 3 months after the last use of antibiotics. Only patients who showed at the final selection, after the pre-trial treatment, two non-adjacent, inter-proximal intra-osseous defects with a probing depth from the buccal and/or lingual aspect of ≥ 6 mm were included. The defects were required to show an angular bony defect of ≥ 4 mm on a new radiograph made at the definitive selection appointment.

Clinical measurements

The level of oral hygiene and the degree of inflammation during the pre-trial period as well as during the actual trial was evaluated on the basis of full-mouth plaque and bleeding scores. After application of erythrosine dye (Merck KGaA, Darmstadt, Germany), the presence or

absence of plaque along the gingival margin was scored at the mesiobuccal, mid-buccal, distobuccal, mesiolingual, mid-lingual and distolingual sites of all teeth. Full-mouth plaque scores were calculated as the percentage of sites harbouring plaque. Full-mouth bleeding scores were calculated as the percentage of sites, measured at six sites for all teeth, that bled upon probing to the bottom of the pocket with a manual PQW probe (Hu-Friedy, Zweigniederlassung, Leimen, Germany). Clinical measurements of the experimental sites at baseline (i.e. directly prior to surgery), 6 and 12 months were performed by the same calibrated investigator (B. G. L.), who was blinded with respect to treatment modality. PPDs were measured with the use of a force-controlled probe (parallel tine, 0.25 N, 127 N/cm²) and automatic readout in one-tenth of a millimetre (Florida Probe[®], Gainesville, FL, USA) (Gibbs et al. 1988). PPD and clinical attachment level (CAL) measurements were carried out at the selected intra-osseous defects from the buccal and lingual aspects. CAL measurements were performed from a custom-made stent margin. PPD and CAL measurements were performed in duplicate, according to the guidelines of the Florida Probe[®] software, and subsequently the mean of the two values was calculated. Probing bone level (PBL) measurements were performed with a PCP UNC-15 probe (Hu-Friedy) after application of local anaesthesia using as much force as needed to feel a bony resistance, and recorded to the nearest half millimetre with the stent margin as reference.

Membrane preparation

The tetracycline-coated e-PTFE membranes were prepared in the following way: type GTA 1 and GTA 2 e-PTFE (Gore-Tex[®], W. L. Gore & Associates Inc., Flagstaff, AZ, USA) barrier membranes were submerged for 1 min. in 5% solution of tridodecylmethylammonium chloride (TDMAC) in absolute alcohol. After drying at room temperature, the TDMAC-coated membranes were immersed for 1 min. into a freshly prepared 3% tetracycline solution (250 mg dissolved in 7.5 ml distilled water, pH adjusted from 1.7 to 9.5 using sodium hydrochloride) and dried at room temperature. Tetracycline-coated e-PTFE membranes were stored in separate ster-

ile containers in the dark at 10°C (Zarkesh et al. 1999).

Surgical procedures

Each patient received a prescription of 0.2% chlorhexidine rinses (Corsodyl[®], GSK, Zeist, The Netherlands) for two rinses a day to be started 1 day before the planned surgical procedure. All surgical procedures were performed by one experienced clinician (F. A.). Full-thickness flaps were raised around both defects. The modified or simplified papilla preservation technique was used depending on the width of the inter-dental space (Cortellini & Tonetti 2000). The flaps were extended to include at least one tooth mesial and distal to the experimental defect involved. These adjacent teeth would provide anchoring for the tetracycline-coated barrier membrane. In addition, the flaps were extended apically to ensure that the barrier at placement would rest on bone along its entire peri-defect extension. Granulation tissue was removed, and root surfaces were planed with hand instruments and ultrasonics with saline cooling (EMS[®], Electro Medical Systems, Nyon, Switzerland). In order not to compromise the vascularization of the flaps, no horizontal periosteal-releasing incisions were performed.

Clinical measurements to describe the defect were recorded, including the number of walls, and the width of the defect. To evaluate to what extent measurements of the clinical PBL reflect the actual bone level, surgical PBLs (SPBL) were measured during surgery by measuring from the deepest point of the defect with a PCP UNC-15 probe to the nearest half millimetre with the stent margin as reference.

By an aselect numbers randomization procedure, it was determined as to which defect would receive treatment with EMP alone or EMP in conjunction with a membrane (MEMP). For the randomization procedure, a randomization list and randomization envelopes were prepared. EMP (Emdogain Gel[®], Biora AB, Malmö, Sweden) was prepared 15 min. before surgical use. The sites were kept free from bleeding as much as possible. The root surface was conditioned for 2 min. with 24% ethylenediamine tetraacetic acid gel (pH 6.7) (PrefGel[®], Biora AB) and after thoroughly rinsing with sterile saline, EMP was applied on the exposed root surface followed by sutur-

ing with e-PTFE sutures (Gore-Tex[®], W. L. Gore & Associates Inc.). For the MEMP site, a tetracycline-coated e-PTFE barrier was trimmed for coverage of the selected defect and sutured around the neck of the tooth in a tent-like fashion and lifted prior to root conditioning and application of EMP. Flaps over both defects were sutured with the intention to achieve primary closure. The duration of surgery was recorded for the EMP and MEMP site separately. Finally, post-operative instructions for pain control with acetaminophen tablets (paracetamol 500 mg) were provided to the patient.

Post-operative procedures and follow-up

Each patient was instructed to continue chlorhexidine rinses for 8 weeks post-operatively. Control of chlorhexidine compliance, gentle polishing with minimum amounts of pumice to remove plaque and chlorhexidine staining were performed at week 1, 2 and 4 post-operatively. Sutures were removed after 2 weeks. Sutures that loosened prematurely were removed. The extent of membrane exposure was recorded in millimetres with a PQW probe at each visit. The barrier membranes were removed in a second-stage surgery after 6 weeks, using local anaesthesia. The sutures for the second stage were removed after 1 week. Patients were asked at each visit up to 2 months whether they felt any discomfort at one or both of the treated sites. The amount of acetaminophen used by the patient was documented. Oral hygiene compliance was checked, and gentle supragingival scaling and careful polishing of the tooth surfaces were performed monthly until month 6, followed by checkups at months 9 and 12.

Statistical analysis

From the baseline buccal and lingual mean PPD measurements of each intra-osseous lesion, the deepest was selected for further analysis throughout the study. From the PPD and CAL measurements, changes in the location of the gingival margin (gingival recession) were calculated (REC). The primary outcome variables were CAL and PBL. Furthermore, full-mouth percentual scores of plaque and bleeding were calculated as a marker of periodontal condition and patient compliance. EMP and MEMP sites were compared within patients. A 2 × 2 level repeated measure

Table 1. Mean values of the clinical parameters $\pm$ standard deviation at baseline and 6 and 12 months ($n = 24$ defects in 11 patients)

	Baseline	6 months	12 months	Difference baseline – 12 months	<i>p</i> -value*
PPD					
EMP	6.95 $\pm$ 1.06	4.69 $\pm$ 0.99	4.09 $\pm$ 1.17	2.86 $\pm$ 0.75	0.0005
MEMP	7.32 $\pm$ 1.24	4.37 $\pm$ 1.33	4.30 $\pm$ 1.08	3.02 $\pm$ 1.55	0.0005
CAL					
EMP	10.94 $\pm$ 1.59	10.00 $\pm$ 1.42	9.66 $\pm$ 1.75	1.28 $\pm$ 2.04	0.0499
MEMP	11.10 $\pm$ 1.60	9.65 $\pm$ 1.59	9.45 $\pm$ 1.74	1.65 $\pm$ 1.29	0.0005
PBL					
EMP	12.83 $\pm$ 2.31	11.42 $\pm$ 2.07	11.21 $\pm$ 1.88	1.63 $\pm$ 1.21	0.0029
MEMP	13.17 $\pm$ 1.96	11.92 $\pm$ 2.02	11.58 $\pm$ 1.88	1.58 $\pm$ 1.92	0.0156
REC					
EMP	3.99 $\pm$ 1.93	5.31 $\pm$ 1.08	5.55 $\pm$ 1.31	1.56 $\pm$ 2.30	0.0454
MEMP	3.77 $\pm$ 1.19	5.29 $\pm$ 1.48	5.15 $\pm$ 1.98	1.38 $\pm$ 1.63	0.0226

PPD, probing pocket depth (mm); CAL, clinical attachment level (mm); PBL, probing bone level (mm); REC: recession (mm); dif, difference. *Statistical testing of differences between baseline and 12 months. Wilcoxon signed rank test.

analysis was used to analyse the effect of several covariates on changes in CAL and PBL by entering baseline and 12-month values as dependent variables and entering baseline full-mouth plaque and bleeding scores, baseline PPD, defect dimensions, receiving antibiotics, smoking, age and gender as covariates. Since none of the covariates had a significant association with any of the effects in the analyses, all further analyses were performed using Wilcoxon tests, comparing various parameters at each assessment and comparing different assessments through time within defects.

Defects were paired in each patient. In one patient, two pairs were available; all other pairs were located in 10 different patients. The extra pair of defects in the 11th patient was entered into the analysis without further correction as the non-parametric analyses do not allow for it. Since the ratio is 1 extra against 10 in separate patients, the possible disturbing influence of within-patient dependence of the two pairs of defects could be considered as minor. *P*-values <0.05 were accepted as statistically significant. The power of the study, given 2 mm as a significant difference in increments (from baseline to 12 months) between treatments, was calculated to be 0.8 for both CAL and PBL.

Results

From the initial 18 selected subjects, 11 patients (four male, seven female) with, in total, 24 sites (one patient had two paired defects), entered and completed the study. Reasons for withdrawal were insufficient time ($n = 2$), travelling dis-

tance ($n = 1$) and insufficient compliance ($n = 1$). Three patients showed reduction of PPD and radiographic defect depth after the pre-trial treatment, to such an extent that they did not fulfil the inclusion criteria anymore.

At baseline, the mean age of the patients was 34.8 years (range 18.0–51.0 years). Three patients were smokers with a mean of 7.5 packyears (range 2.0–20.0 packyears); one patient was a former smoker and stopped smoking 26 years ago (8.0 packyears). Seven out of the 11 patients entering the study who were culture positive for *A. actinomycetemcomitans* after initial therapy were treated by means of re-scaling and root planing in conjunction with systemic amoxicillin and metronidazole.

The patients maintained good levels of oral hygiene throughout the study. At baseline, the mean full-mouth plaque score was 5.4% (range 2.0–8.0%) and the full-mouth bleeding score was 6.7% (range 1.0–12.0%). At 6 months, the mean full-mouth plaque score was 11.8% (range 4.0–29.0%) and the mean full-mouth bleeding score was 3.9% (range 1.0–7.0%). At 12 months, the data showed a mean full-mouth plaque score of 12.5% (range 1.0–38.0%) and a mean bleeding score of 6.0% (range 1.0–17.0%).

The mean PPD at baseline was 7.0 mm (range 6.0–9.4 mm) for the EMP sites and 7.3 mm (range 6.1–10.6 mm) for the MEMP sites (Table 1). After 12 months, the EMP sites showed a mean PPD reduction of 2.9 mm (range 1.8–4.1 mm), a mean gain of CAL of 1.3 mm (range 3.5 mm loss–4.5 mm gain), a mean gain of PBL of 1.6 mm

(range 0.5 mm loss–3.0 mm gain) and a mean increase of REC of 1.6 mm (range 1.6 mm decrease–6.1 mm increase). The MEMP sites showed a mean PPD reduction of 3.0 mm (range 1.1–5.6 mm), a mean gain of CAL of 1.7 mm (range 0.1 mm–3.9 mm), a mean gain of PBL of 1.6 mm (range 0.5 mm loss–5.5 mm gain) and a mean increase of REC of 1.4 mm (range 1.8 mm decrease–3.8 mm increase). Again, no statistically significant differences in the amount of plaque and bleeding on a site level were found. No statistically significant difference was found between 6 and 12 months with regard to PPD, CAL, PBL and REC results. Twelve months after baseline, the clinical parameters PPD, CAL, PBL showed a significant improvement, together with a significantly increased amount of REC compared with baseline. However, no statistically significant differences were found between the two treatment modalities EMP and MEMP (Table 1).

Table 2 shows data on PPD, CAL and PBL for individual sites. Of the MEMP sites, none of the defects experienced loss of clinical attachment, whereas of the EMP sites, three defects experienced loss of clinical attachment. In both groups, only one defect showed loss of PBL.

The anatomy of the intra-osseous component of the lesions was revealed to be three walled in all cases (Table 3). Comparable defect dimensions were found between EMP and MEMP sites. The average depth of the defect, measured from the bottom of the defect to the top of the crest (intra-osseous component), was 4.3 mm (range 3.0–6.5 mm) for the EMP sites and 4.3 mm (range 2.5–6.0 mm) for the MEMP sites (Table 2). Evaluation of the PBL and the SPBL measurements performed on the day of surgery showed no statistically significant difference.

In Table 4, the events related to the surgical treatment are presented. The mean time needed for the surgical procedures was 64.8 min. (range 35.0–115.0 min.) for the EMP site and 73.3 min. (range 28.0–125.0 min.) for the MEMP site. Evaluation of the extent of membrane exposure 6 weeks after surgery showed minor membrane exposure (1–2 mm) in eight MEMP sites and more advanced exposure (≥ 3 mm) in two MEMP sites. Assessment of post-operative discomfort showed that one patient had a loose suture at the EMP site within 1 week, one patient complained about minor post-operative haemorrhage at

Table 2. Individual data on baseline PPD and increments for CAL and PBL for each treatment defect

Site no.	MEMP						EMP				
	patient	tooth	location	baseline PPD	12 months dif CAL	12 months dif PBL	tooth	location	baseline PPD	12 months dif CAL	12 months dif PBL
1	1	36	Mesial	10.6	3.9	5.5	46	Distal	6.3	1.8	3.0
2	2	37	Mesial	6.3	0.1	0.0	46	Mesial	6.0	-0.1	-0.5
3	3	44	Mesial	7.0	2.9	1.0	36	Mesial	8.1	1.3	3.0
4	4	33	Mesial	7.4	0.5	-0.5	43	Mesial	7.6	4.5	1.5
5	5	36	Mesial	7.2	1.8	0.0	46	Mesial	7.2	-0.9	0.5
6	6	24	Mesial	7.6	2.6	2.5	15	Distal	6.2	1.1	1.5
7	7	36	Mesial	7.4	1.6	1.5	46	Mesial	7.7	3.0	1.0
8	8	25	Mesial	6.7	3.3	0.0	36	Distal	6.2	1.5	3.0
9	9	46	Distal	6.5	1.7	1.5	36	Mesial	6.3	2.3	0.0
10	10	46	Mesial	8.6	0.5	3.5	36	Mesial	6.0	2.4	2.5
11*	11	37	Distal	6.1	0.3	0.0	46	Distal	9.4	-3.5	2.5
12*	11	44	Distal	6.4	0.6	4.0	34	Distal	6.4	2.0	1.5

*Two pairs of defects in one patient. PPD, probing pocket depth; CAL, clinical attachment level; EMP, enamel matrix protein; MEMP, EMP in conjunction with a membrane.

Table 3. Clinical characteristics of inter-proximal defects at baseline ($n = 24$ defects in 11 patients)

	EMP	MEMP
Defect dimension (mean $\pm$ SD)		
Width defect bucco-lingual in mm (BL)	9.4 $\pm$ 0.9	9.2 $\pm$ 1.1
Width defect mesio-distal in mm (MD)	3.5 $\pm$ 0.9	3.6 $\pm$ 1.2
Depth defect buccal in mm	4.8 $\pm$ 1.7	4.4 $\pm$ 1.0
Depth defect lingual in mm	3.8 $\pm$ 1.7	4.1 $\pm$ 1.8
Average depth buccal and lingual in mm (D)	4.3 $\pm$ 1.3	4.3 $\pm$ 1.0
Volume defect in mm ³ (BL $\times$ MD $\times$ D)	144.2 $\pm$ 76.2	147.0 $\pm$ 72.1
Probing bone level in mm (mean $\pm$ SD)	12.7 $\pm$ 2.3	12.9 $\pm$ 2.1
Surgical probing bone level in mm (mean $\pm$ SD)	12.1 $\pm$ 2.3	12.6 $\pm$ 2.7

No statistical significant difference between MEMP and EMP defects.

EMP, enamel matrix protein; MEMP, EMP in conjunction with a membrane.

the MEMP site for 2 days, one patient had headaches for 1 week and one patient had a limited mouth opening for 1 week. A significantly shorter period of post-operative pain (mean 1.4 days, range 0–4.0 days) was found in the EMP sites as compared with the MEMP sites (mean of 3.5 days, range 1.0–7.0 days). Relatively few days of discomfort were recorded at the MEMP sites after membrane removal (mean 0.2 days, range 0–1.0 days). During the first 7 post-operative weeks, a mean of 8.2 tablets (range 0–34 tablets) of acetaminophen was used. Because of the fact that both treatment modalities were carried out within each patient, the use of tablets could not be evaluated for EMP and MEMP sites separately.

The repeated measures analysis did not show a significant influence of baseline full-mouth plaque and bleeding scores, baseline PPD, defect dimensions, receiving of antibiotics, smoking, age and gender on changes of CAL and PBL in the analysis.

Discussion

The results of the present investigation showed that treatment of deep inter-proximal intra-osseous defects with EMP with or without an adjunctive tetracycline-coated barrier membrane resulted in a statistically significant mean PPD reduction, gain in attachment level, gain in bone level and some gingival recession. There were, however, no significant differences between treatment results when comparing the two treatment modalities. The results of the present MEMP procedure are comparable with other GTR studies (Kersten et al. 1992, Weltman et al. 1997, Mayfield et al. 1998, Zucchelli et al. 1999, Loos et al. 2002, Minabe et al. 2002). In contrast to the present findings, much larger attachment level gains have been reported by a number of other clinical trials using GTR (Cortellini et al. 1995), EMP (Heden et al. 1999, Sculean et al. 1999a, b, c, Heden 2000) or both (Pon- toriero et al. 1999, Sculean et al. 2001a).

A number of factors that may have influenced the present results can be suggested. First, a major difference between the present study and other reports relates to the pre-trial treatment. The current pre-trial treatment included not only the use of systemic antibiotics in a number of subjects but also the re-treatment of the selected experimental sites by scaling and root planing. It has been demonstrated that the presence of *A. actinomycetemcomitans* may have a negative influence on the outcome of periodontal therapy (Machtei et al. 1994). Therefore, it was decided to treat all patients who were culture positive for *A. actinomycetemcomitans* after initial therapy by means of re-scaling and root planing in conjunction with systemic amoxicillin and metronidazole. This treatment has been shown to be highly effective in eradicating *A. actinomycetemcomitans* (Pavicic et al. 1994, Berglundh et al. 1998).

It has been suggested that the pre-trial treatment negatively influences the potential of defects to regenerate. Inflamed lesions may respond more favourably to surgery than lesions that have been extensively instrumented prior to surgery; this may be because of more open marrow spaces, presence of immature collagen and tissue factors (Prichard 1957, Becker et al. 1986, Becker 1994). Results of the present study might indeed corroborate the suggestion that extensive scaling and root planing of an intra-osseous site prior to regenerative procedures could result in limited gains in clinical attachment and new bone. Thus, one has to keep in mind that extensive pre-trial treatment actually changes the baseline values of all

Table 4. Events related to surgical treatment (mean $\pm$ SD)

Duration surgery (min)						
EMP						64.8 ± 26.6
MEMP						73.3 ± 29.0
Membrane removal						
	week 1	week 2	week 4	week 6	total	
Exposure membrane (no. of sites)						
MEMP 1–2 mm	3	6	7	8	8	
MEMP ≥3 mm	1	1	2	2	2	
Post-operative pain (no. of days)						
EMP	1.1 ± 0.8	0.2 ± 0.6	0	0	0.2 ± 0.6	1.4 ± 1.4
MEMP	2.6 ± 1.7	0.7 ± 1.7	0	0	0.2 ± 0.4	3.5 ± 2.2*
Acetaminophen (no. of tablets)						
EMP+MEMP	7.3 ± 8.4	0.3 ± 0.6	0	0	0.5 ± 1.0	8.2 ± 9.6

*Statistically significant more pain MEMP sites; Wilcoxon signed rank test p -value 0.0078.

EMP, enamel matrix protein; MEMP, EMP in conjunction with a membrane.

clinical parameters. Measures of PPD and CAL will already be more favourable than before pre-trial treatment. When comparing data from studies that provide no or limited pre-treatment of experimental sites to studies that perform extensive pre-treatment, the baseline values before all treatment should be taken into account. In that case, conclusions should be based on the total change of parameters because of the whole series of treatments provided. In the present study, data do not allow for such a comparison.

Of the 12 membrane-treated sites, 10 showed exposure of the membrane to some degree. This occurrence could have a negative effect on the treatment outcomes since it has been shown that exposure of the membrane is related to less gain in attachment level (Becker et al. 1988, Cortellini et al. 1990, 1993, De Sanctis et al. 1996). However, the tetracycline coat may have limited these potential negative effects.

Defect morphology has been shown to influence the potential for regeneration (Renvert et al. 1985, Tonetti et al. 1993, Pontoriero et al. 1999). In the present study, all lesions were three-wall intra-osseous defects providing enough support for the membrane in order not to collapse, and providing stabilization of the intra-osseous cloth formation (Trombelli et al. 1997, Mayfield et al. 1998).

No effects of smoking on the CAL or PBL were found in the present data. This is in contrast to several previous studies, which showed that smoker

patients demonstrated less gain in CAL and PBL than non-smoker patients (e.g. Tonetti et al. 1998, 2002, Loos et al. 2002). Most likely, the small number of smokers ($n = 3$) in the current study is responsible for this lack of effect.

In the present study, defects were treated either by EMP or by EMP plus a membrane coated with tetracycline. EMP on itself has been reported to have positive and stimulatory effects on cells originating from the periodontal ligament (Van der Pauw et al. 2000, Lyngstadaas et al. 2001). Moreover, EMP has inhibitory effects on bacteria, in particular, it may help to prevent bacterial colonization of the root surface that is targeted for regeneration, i.e. deposition of new cementum with insertion of new periodontal ligament fibres (Arweiler et al. 2002, Spahr et al. 2002). It is generally thought that periodontal ligament cells cannot re-populate the root surface where bacteria form colonies. While EMP acts supposedly at the level of the root surface, it has been our thought that the local application of tetracycline from the membrane as a vehicle prevents infection of the blood clot and infection of flap margins. Tetracycline is bacteriostatic and effective against Gram-positive bacteria, and many periodontal pathogens (Walker et al. 1981, Baker et al. 1985a,b). Tetracycline has the characteristic to adhere to dentin surfaces, known as substantivity (Stabholz et al. 1993). It has been shown to inhibit tissue collagenase activity, reduce alveolar bone resorption (Golub et al. 1984) and pro-

mote fibroblast adhesion and growth (Terranova et al. 1986). The tetracycline coat to the membrane has been shown to have an in vitro antimicrobial activity for 2–6 weeks, demonstrating its excellent potential to prevent bacterial colonization of the membrane (Zarkesh et al. 1999). The extended antibacterial activity is obtained by the strong coupling to the membrane and slow release. Thus, a combined periodontal ligament stimulatory and bacteriostatic approach was hypothesized to enhance GTR results. However, this hypothesis is not substantiated by the results; sites treated with the combination do not respond substantially better than sites treated with EMP alone.

In conclusion, within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of clinical attachment and bone.

Acknowledgements

Part of this study was supported by W. L. Gore & Associates Inc., Flagstaff, AZ and Biora AB, Malmö, Sweden.

References

- Abbas, F., Wennström, J., Van der Weijden, F. A., Schneiders, T. & Van der Velden, U. (2003) Surgical treatment of gingival recessions using Emdogain Gel: clinical procedure and case reports. *International Journal of Periodontics & Restorative Dentistry* **23**, 607–613.
- Arweiler, N. B., Ausschill, T. M., Donos, N. & Sculean, A. (2002) Antibacterial effect of an enamel matrix protein derivative on in vivo dental biofilm vitality. *Clinical Oral Investigations* **4**, 205–209.
- Baker, P. J., Evans, R. T., Slots, J. & Genco, R. J. (1985a) Antibiotic susceptibility of anaerobic bacteria from the human oral cavity. *Journal of Dental Research* **64**, 1233–1244.
- Baker, P. J., Evans, R. T., Slots, J. & Genco, R. J. (1985b) Antibiotic susceptibility of human oral anaerobic bacteria to antibiotics suitable for topical use. *Journal of Clinical Periodontology* **12**, 201–208.
- Becker, W. (1994) *Periodontal regeneration. Current status and directions*, pp. 137–150. Chicago: Quintessence Publishing Co Inc.
- Becker, W., Becker, B. E., Berg, L., Prichard, J., Caffesse, R. & Rosenberg, E. (1988) New attachment after treatment with root isolation procedures: report for class II and class II furcations and vertical osseous defects. *International Journal of Periodontics & Restorative Dentistry* **8**, 8–23.

- Becker, W., Becker, B. E., Berg, L. & Samsam, C. (1986) Clinical and volumetric analysis of three-wall intrabony defects following open flap debridement. *Journal of Periodontology* **5**, 277–285.
- Berglundh, T., Krok, L., Liljenberg, B. & Westfelt, E. (1998) The use of metronidazole and amoxicillin in the treatment of advanced periodontal disease. A prospective, controlled clinical trial. *Journal of Clinical Periodontology* **25**, 354–362.
- Bouchard, P., Giovannoli, J. L., Mattout, C., Davarpanah, M. & Etienne, D. (1997) Clinical evaluation of a bioabsorbable regenerative material in mandibular class II furcation therapy. *Journal of Clinical Periodontology* **24**, 511–518.
- Caffesse, R. G., Mota, L. F., Quinones, C. R. & Morrison, E. C. (1997) Clinical comparison of resorbable and non-resorbable barriers for guided periodontal tissue regeneration. *Journal of Clinical Periodontology* **24**, 747–752.
- Cortellini, P., Pini Prato, G., Baldi, C. & Clauser, C. (1990) Guided tissue regeneration with different materials. *International Journal of Periodontics & Restorative Dentistry* **10**, 137–151.
- Cortellini, P., Pini Prato, G. & Tonetti, M. S. (1993) Periodontal regeneration of human infrabony defects. I. Clinical measures. *Journal of Periodontology* **64**, 254–260.
- Cortellini, P., Pini Prato, G. & Tonetti, M. S. (1995) Periodontal regeneration of human intrabony defects with titanium reinforced membranes. A controlled clinical trial. *Journal of Periodontology* **23**, 797–803.
- Cortellini, P., Pini Prato, G. & Tonetti, M. S. (1996) Long-term stability of clinical attachment following guided tissue regeneration and conventional therapy. *Journal of Clinical Periodontology* **23**, 106–111.
- Cortellini, P. & Tonetti, M. S. (2000) Focus on intrabony defects: guided tissue regeneration. *Periodontology 2000* **22**, 104–132.
- De Sanctis, M., Clauser, C. & Zucchelli, G. (1996) Bacterial colonization of resorbable barrier materials and periodontal regeneration. *Journal of Periodontology* **67**, 1193–1200.
- Froum, S. J., Weinberg, M. A., Rosenberg, E. & Tarnow, D. (2001) A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: a 12 month re-entry study. *Journal of Periodontology* **72**, 25–34.
- Gestrelus, S., Andersson, C., Johansson, A. C., Persson, E., Brodin, A., Rydhag, L. & Hammarström, L. (1997a) Formulation of enamel matrix derivative for surface coating. Kinetics and cell colonization. *Journal of Clinical Periodontology* **24**, 678–684.
- Gestrelus, S., Andersson, C., Lidstrom, D., Hammarström, L. & Somerman, M. (1997b) In vitro studies on periodontal ligament cells and enamel matrix derivative. *Journal of Clinical Periodontology* **24**, 685–692.
- Gibbs, C. H., Hirschfeld, J. W., Lee, J. D., Low, S. B., Magnusson, I., Thousand, R. R., Yereni, P. & Clark, W. B. (1988) Description and evaluation of a new computerized periodontal probe – the Florida Probe. *Journal of Periodontology* **64**, 1157–1165.
- Golub, L. M., Ramamurthy, N., McNamara, T. F. & Gomes, B. (1984) Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. *Journal of Periodontal Research* **19**, 651–655.
- Goodson, J. M. (1989) Pharmacokinetic principles controlling efficacy of oral therapy. *Journal of Dental Research* **68**, 1625–1632.
- Gottlow, J., Nyman, S., Lindhe, J., Karring, T. & Wenström, J. (1986) New attachment formation in the human periodontium by guided tissue regeneration. *Journal of Clinical Periodontology* **13**, 604–616.
- Grossi, S. G., Genco, R. J., Machtei, E. E. & Ho, A. W. (1995) Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. *Journal of Periodontology* **66**, 23–29.
- Hammarström, L., Heijl, L. & Gestrelus, S. (1997) Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. *Journal of Clinical Periodontology* **24**, 669–677.
- Heden, G. (2000) A case report study of 72 consecutive Emdogain-treated intrabony periodontal defect: clinical and radiographic findings after 1 year. *International Journal of Periodontics & Restorative Dentistry* **20**, 127–139.
- Heden, G., Wennström, J. & Lindhe, J. (1999) Periodontal tissue alterations following Emdogain® treatment of periodontal sites with angular bone defects. A series of case reports. *Journal of Clinical Periodontology* **26**, 855–860.
- Heijl, L. (1997) Periodontal regeneration with enamel matrix derivative in one human experimental defect. A case report. *Journal of Clinical Periodontology* **24**, 693–696.
- Heijl, L., Heden, G., Svärdsström, G. & Östgren, A. (1997) Enamel matrix derivative (Emdogain®) in the treatment of intrabony periodontal defects. *Journal of Clinical Periodontology* **24**, 705–714.
- Hoang, A. M., Oates, T. W. & Cochran, D. L. (2000) In vitro wound healing responses to enamel matrix derivative. *Journal of Periodontology* **71**, 1270–1277.
- Kersten, B. G., Chamberlain, A. D., Khorsandi, S., Wikesjö, U. M., Selvig, K. A. & Nilveus, R. E. (1992) Healing of the intrabony periodontal lesion following root conditioning with citric acid and wound closure including an expanded PTFE membrane. *Journal of Periodontology* **63**, 876–882.
- Kornman, K. S. & Robertson, P. B. (2000) Fundamental principles affecting the outcomes of therapy for osseous lesions. *Periodontology 2000* **22**, 22–43.
- Loos, B. G., Louwerse, P. H. G., Van Winkelhoff, A. J., Burger, W., Gilijamse, M., Hart, A. M. & Van der Velden, U. (2002) Use of barrier membranes and systemic antibiotics in the treatment of intraosseous defects. *Journal of Clinical Periodontology* **29**, 910–921.
- Lyngstadaas, S. P., Lundberg, E., Ekdahl, H., Andersson, C. & Gestrelus, S. (2001) Autocrine growth factors in human periodontal ligament cells cultured on enamel matrix derivative. *Journal of Clinical Periodontology* **28**, 181–188.
- Machtei, E. E., Cho, M. I., Dunford, R., Norderyd, J., Zambon, J. J. & Genco, R. J. (1994) Clinical, microbiological, and histological factors which influence the success of regenerative periodontal therapy. *Journal of Periodontology* **65**, 154–161.
- Mayfield, L., Söderholm, G., Hallström, H., Kullendorff, B., Edwardsson, S., Brathall, G., Brägger, U. & Attström, R. (1998) Guided tissue regeneration for the treatment of intraosseous defects using a bioabsorbable membrane. A controlled clinical study. *Journal of Clinical Periodontology* **25**, 585–595.
- Mellonig, J. T. (1999) Enamel matrix derivative for periodontal reconstructive periodontal surgery: Technique and clinical and histologic case report. *International Journal of Periodontics & Restorative Dentistry* **19**, 9–19.
- Minabe, M., Kodama, T., Kogou, T., Takeuchi, K., Fushimi, H., Sugiyama, T. & Mitarai, E. (2002) A comparative study of combined treatment with a collagen membrane and enamel matrix proteins for the regeneration of intraosseous defects. *International Journal of Periodontics & Restorative Dentistry* **22**, 595–605.
- Mombelli, A., Lang, N. P. & Nyman, S. (1993) Isolation of periodontal species after guided tissue regeneration. *Journal of Periodontology* **64**, 1171–1175.
- Nowzari, H., McDonald, E. S., Flynn, J., London, R. M., Morrison, J. L. & Slots, J. (1996) The dynamics of microbial colonization of barrier membranes for guided tissue regeneration. *Journal of Periodontology* **67**, 694–702.
- Pavicic, M. J. A. M. P., Van Winkelhoff, A. J., Douqué, N. H. & Steures, R. W. R. (1994) Microbiological and clinical effects of metronidazole and amoxicillin in *Actinobacillus actinomycetemcomitans*-associated periodontitis: a 2 year evaluation. *Journal of Clinical Periodontology* **21**, 107–112.
- Pontoriero, R., Wennström, J. & Lindhe, J. (1999) The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. *Journal of Clinical Periodontology* **26**, 833–840.
- Prichard, J. F. (1957) The intrabony technique as a predictable procedure. *Journal of Periodontology* **28**, 202.
- Renvert, S., Nilvéus, R. & Egelberg, J. (1985) Healing after treatment of periodontal intraosseous defects. V. Effect of root planing versus flap surgery. *Journal of Clinical Periodontology* **12**, 619–629.
- Sculean, A., Donos, N., Blaes, A., Lauermaun, M., Reich, E. & Brex, M. (1999a) Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony defects. A split mouth study. *Journal of Periodontology* **70**, 255–262.
- Sculean, A., Donos, N., Brex, M., Reich, E. & Karring, T. (2000) Treatment of intrabony defects with enamel matrix proteins and

- guided tissue regeneration. An experimental study in monkeys. *Journal of Clinical Periodontology* **27**, 466–472.
- Sculean, A., Donos, N., Miliauskaitė, A., Arweiler, N. & Brex, M. (2001b) Treatment of intrabony defects with enamel matrix proteins or bioabsorbable membranes. A 4-year follow-up split-mouth study. *Journal of Periodontology* **72**, 1695–1701.
- Sculean, A., Donos, N., Windisch, P., Brex, M., Gera, I., Reich, E. & Karring, T. (1999b) Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration. *Journal of Periodontal Research* **34**, 310–322.
- Sculean, A., Reich, E., Chiantella, G. C. & Brex, M. (1999c) Treatment of intrabony periodontal defects with an enamel matrix protein derivative (Emdogain): a report of 32 cases. *International Journal of Periodontics & Restorative Dentistry* **19**, 157–163.
- Sculean, A., Windisch, P., Chiantella, G. C., Donos, N., Brex, M. & Reich, E. (2001a) Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. A prospective controlled clinical study. *Journal of Clinical Periodontology* **28**, 397–403.
- Selvig, K. A., Kersten, B. G., Chamberlain, A. D. H., Wikesjö, U. M. E. & Nilveus, R. E. (1992) Regenerative surgery of intrabony periodontal defects using ePTFE barrier membranes: Scanning electron microscopic evaluation of retrieved membranes versus clinical healing. *Journal of Periodontology* **63**, 974–978.
- Silvestri, M., Ricci, G., Rasperini, G. & Sartori, S. (2000) Comparison of treatments of intrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap. A pilot study. *Journal of Clinical Periodontology* **27**, 603–610.
- Slots, J., Smith MacDonald, E. & Nowzari, H. (1999) Infectious aspects of periodontal regeneration. *Periodontology 2000* **19**, 164–172.
- Smith MacDonald, E., Nowzari, H., Contreras, A., Flynn, J., Morrison, J. & Slots, J. (1998) Clinical and microbial evaluation of a bioabsorbable and a nonresorbable barrier membrane in the treatment of periodontal intraosseous lesions. *Journal of Periodontology* **69**, 445–453.
- Spahr, A., Lyngstadaas, S. P., Boek, C., Andersson, C., Podbielski, A. & Haller, B. (2002) Effect of the enamel matrix derivative Emdogain® on the growth of periodontal pathogens in vitro. *Journal of Clinical Periodontology* **29**, 62–72.
- Stabholz, A., Kettering, J., Aprecio, R. & Zimmerman, G. (1993) Retention of antimicrobial activity by human root surfaces after in situ subgingival irrigation with tetracycline HCL or chlorhexidine. *Journal of Periodontology* **64**, 137–141.
- Terranova, V. P., Franzetti, L. C., Hic, S. & DiFlorio, R. M. (1986) A biochemical approach to periodontal regeneration: tetracycline treatment of dentin promotes fibroblast adhesion and growth. *Journal of Periodontal Research* **21**, 330–337.
- Tonetti, M., Pini Prato, G. & Cortellini, P. (1993) Periodontal regeneration of human infrabony defects. IV. Determinants of healing response. *Journal of Periodontology* **64**, 934–940.
- Tonetti, M. S. & Cortellini, P. (1997) Case selection and treatment considerations of guided tissue regeneration in deep intrabony defects. *Current Opinion in Periodontology* **4**, 82–88.
- Tonetti, M. S., Cortellini, P., Suvan, J. E., Adriaens, P., Baldi, C., Dubravec, D., Fonzar, A., Fourmoussis, I., Magnani, C., Muller-Campanile, V., Patroni, S., Sanz, M., Vangsted, T., Zabalegni, I., Pini Prato, G. & Lang, N. P. (1998) Generalizability of the added benefits of guided tissue regeneration in the treatment of deep intrabony defects. Evaluation in a multi-center randomized controlled clinical trial. *Journal of Periodontology* **69**, 1183–1192.
- Tonetti, M. S., Lang, N. P., Cortellini, P., Suvan, J. E., Adriaens, P., Dubravec, D., Fonzar, A., Fourmoussis, I., Mayfield, L., Rossi, R., Silvestri, M., Tiedemann, C., Topoll, H., Vangsted, T. & Walkamm, B. (2002) Enamel matrix proteins in the regenerative therapy of deep intrabony defects. A multicentre randomized controlled clinical trial. *Journal of Clinical Periodontology* **29**, 317–325.
- Trombelli, L., Kim, C. K., Zimmerman, G. J. & Wikesjö, U. M. (1997) Retrospective analysis of factors related to clinical outcome of guided tissue regeneration procedures in intrabony defects. *Journal of Clinical Periodontology* **6**, 366–371.
- Van der Pauw, M., Van den Bos, T., Everts, V. & Beertsen, W. (2000) Enamel matrix-derived protein stimulates attachment of periodontal ligament fibroblasts and enhances alkaline phosphatase activity and TGFβ1 release of periodontal ligament and gingival fibroblasts. *Journal of Periodontology* **71**, 31–43.
- Van Winkelhoff, A. J., Rams, T. E. & Slots, J. (1996) Systemic antibiotic therapy in periodontics. *Periodontology 2000* **10**, 45–78.
- Walker, C. B., Gordon, J. M., McQuilkin, S. J. & Niebloom, T. A. (1981) Tetracycline: Levels achievable in gingival crevice fluid and in vitro effect on subgingival organisms. Part II. Susceptibilities of periodontal bacteria. *Journal of Periodontology* **52**, 613–616.
- Walker, C. B., Pappas, J. D., Tyler, K. Z., Cohen, S. & Gordon, J. M. (1985) Antibiotic susceptibilities of periodontal bacteria. In vitro susceptibilities to eight antimicrobial agents. *Journal of Periodontology* **56**, 67–74.
- Weltman, R., Trejo, P. M., Morrison, E. & Caffesse, R. (1997) Assessment of guided tissue regeneration procedures in intrabony defects with bioabsorbable and non-resorbable barriers. *Journal of Periodontology* **68**, 582–590.
- Zarkesh, N., Nowzari, H., Morrison, J. L. & Slots, J. (1999) Tetracycline-coated polytetrafluoroethylene barrier membranes in the treatment of intraosseous periodontal lesions. *Journal of Periodontology* **70**, 1008–1016.
- Zucchelli, G., Pollini, F., Clauser, C. & De Sanctis, M. (2000) The effect of chlorhexidine mouthrinses on early bacterial colonization of guided tissue regeneration membranes. *Journal of Periodontology* **71**, 263–271.
- Zucchelli, G., Sforza, N. M., Clauser, C., Cesari, C. & De Sanctis, M. (1999) Topical and systemic antimicrobial therapy in guided tissue regeneration. *Journal of Periodontology* **70**, 239–247.

Address:
U. van der Velden
Department of Periodontology
Academic Center for Dentistry Amsterdam
(ACTA)
Louwesweg 1
1066 EA Amsterdam
The Netherlands
E-mail: u.vd.velden@acta.nl